Precision in Neuropsychiatry

What is the problem?

The diagnosis of neuropsychiatric disorders still relies mostly on clinicians’ subjective impression of the patients’ clinical history, human eye-inspection of brain scans and memory.

Neuropsychiatric disorders such as Alzheimer’s and Parkinson’s are particularly difficult to diagnose, especially in its early stages, as symptoms are mild, unspecific and brain changes still subtle. In fact, at the time of the first appointment, 30% of Alzheimer’s and about 10% of Parkinson’s patients are misdiagnosed.

An incorrect or delayed diagnosis entails late and potentially harmful treatments and unnecessary costs.

We support clinicians for a more timely and confident diagnosis.

By applying Artificial Intelligence to brain scan data (magnetic resonance imaging or nuclear medicine imaging), NeuroPsyCAD is able to recognize disease ‘signatures’ in a new patient’s brain scan.

Earlier diagnosis

We provide, in hours, a report containing a probability score per disease and per patient.

Better Care

By applying Artificial Intelligence to brain scan data, NeuroPsyCAD allows a personalized and early treatment.

Lower Costs

With NeuroPsyCAD’s report, diagnosis can be 5 times less costly than what is currently achieved.

Who are our partners?

We have now established several national and international clinical partnerships in order to expand our service.

We have also on board an expert advisory board, with key opinion leaders in neurology and psychiatry from the UK, Finland and Portugal.

Newsletter Signup

Sign up to our newsletter to receive the most recent updates from our team.